Roche and Zymeworks Strike $55M Deal on Trispecific Challenger to Amgen’s Imdelltra
Roche is paying Zymeworks $55M upfront for ZW209, a trispecific antibody designed to improve on Amgen’s Imdelltra in small-cell lung cancer.
Roche is paying Zymeworks $55M upfront for ZW209, a trispecific antibody designed to improve on Amgen’s Imdelltra in small-cell lung cancer.
Evaxion stock up on durable three-year EVX-01 results in melanoma. Immune hit rate reached 89%, but only 6 patients continued on monotherapy.
The FDA lifted the clinical hold on ARD-101, allowing Aardvark Therapeutics to resume development for Prader-Willi Syndrome after cardiac safety studies.
Biohaven’s Vyglxia resubmission for SCA accepted for review by the FDA. Target action date is the first quarter of 2027.
EQT is offering €46.50 per share for Qiagen, a 40.3% premium to the unaffected price.
Positive CLARITY Phase 3 data for brepocitinib in uveitis lifts Roivant stock. Median time to treatment failure exceeded 48 weeks.